{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-22-001521","form_type":"8-K","ticker":"CVSA","cik":"0000730464","company_name":"Covista Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.395111+00:00","generated_at":"2026-06-22T10:23:03.887979+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Adtalem Q1 revenue $354.6M (+22.7%); adjusted EPS $0.88 (+151%); margins expand","bullets":["Revenue $354.6M up 22.7% YoY; diluted EPS $0.05 vs loss of $1.17; adjusted EPS $0.88 up 151.4%.","Adjusted operating income $65.1M up 78.7%; adjusted EBITDA $82.1M up 62.6%; margin expanded to 23.1% from 17.5%.","Gross debt reduced by $101M (11.7%) in Q1.","Segment: Chamberlain revenue flat, enrollment -4%; Walden enrollment -9.2%; Medical/Vet enrollment +3.4%.","Reaffirmed FY2023 guidance: revenue $1,380M-$1,450M, adjusted EPS $3.95-$4.20."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-22-001521","json":"https://secwatch.observer/filing/0001157523-22-001521.json","markdown":"https://secwatch.observer/filing/0001157523-22-001521.md","text":"https://secwatch.observer/filing/0001157523-22-001521.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/730464/000115752322001521/0001157523-22-001521-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/730464/000115752322001521/a52959534.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T10:23:03.887979+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1b258ca1fa65deaa1040856665db07dec5c777ef","claim":"Covista Inc. reported first quarter fiscal 2023 ended Sept. 30, 2022 results: revenue $354.6 million, net income $2.2 million, EPS $0.05. Guidance reaffirmed.","evidence_excerpt":"healthcare professionals while driving superior student outcomes. ” Financial Highlights Selected financial data for the three months ended Sept. 30, 2022: ● Revenue of $354.6 million increased 22.7% compared with the prior year due to the timing of the acquisition of Walden ● Diluted earnings per share increased to $0.05 from a loss of $1.17 in the prior","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/730464/000115752322001521/0001157523-22-001521-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter fiscal 2023 ended Sept. 30, 2022"},{"label":"Revenue","value":"$354.6 million"},{"label":"Net income","value":"$2.2 million"},{"label":"EPS","value":"$0.05"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}